IRVINE, Calif., Sept. 19, 2013 /PRNewswire/ -- AtheroNova
Inc. (OTCBB: AHRO), a biotech company focused on the research and
development of compounds to safely regress atherosclerotic plaque
and improve lipid profiles in humans, today announced that Chairman
and CEO, Thomas W. Gardner, will
present a corporate overview at the 2013 Aegis Capital Healthcare
Conference. The presentation will take place at 9:00am PT on Saturday,
September 28 at The Encore at Wynn in Las Vegas, NV.
In addition to the presentation, Mr. Gardner will be available
to meet with analysts, industry executives and investors in
one-on-one meetings. Those interested in meeting with Mr.
Gardner during the Conference are encouraged to contact the Company
directly at info@atheronova.com.
About AtheroNova
AtheroNova Inc. is a biotechnology company focused on the
discovery, research, development and licensing of novel compounds
to safely reduce or regress atherosclerotic plaque deposits and
improve lipid profiles in humans. In addition to its lead compound
AHRO-001, AtheroNova plans to develop multiple applications for its
patented and patents-pending therapies in market sectors that
include: Cardiovascular Disease, Stroke, Peripheral Artery Disease,
Dementia and Alzheimer's and Erectile Dysfunction, all of which
have been linked to atherosclerosis. Atherosclerosis and its
related pharmaceutical expenses for these indications cost
consumers more than $41 billion
annually in the United States
alone. For more information, please visit www.AtheroNova.com.
Forward-Looking Statements
This news release includes "forward-looking statements"
within the meaning of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. These
statements are based upon the current beliefs and expectations of
AtheroNova's management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks
or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to,
general industry conditions and competition; significant
fluctuations in expenses associated with clinical trials, failure
to secure additional financing, the inability to complete
regulatory filings with the Food and Drug Administration,
general economic factors, including interest rate and currency
exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global
trends toward health care cost containment; technological advances,
new products and patents attained by competitors; challenges
inherent in new product development, including obtaining regulatory
approval; AtheroNova's ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of AtheroNova's patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
AtheroNova undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in AtheroNova's 2012 Annual
Report on Form 10-K and the company's other filings with the
Securities and Exchange Commission (SEC) available at the SEC's
Internet site (www.sec.gov).
SOURCE AtheroNova Inc.